This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...
The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
As per DelveInsight estimates, North America is anticipated to dominate the global biologics drug substance manufacturing market during the forecast period. In the biologics type segment of the ...
Dr. Hing C. Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a ...
The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics ...
HCW Biologics Inc. has announced the FDA's approval of its Investigational New Drug Application to begin a Phase 1 clinical trial for HCW9302, a new immunotherapy targeting alopecia areata ...
Dr. Hing C. Wong, Founder and CEO of HCW Biologics, expressed optimism about the trial, stating, "The FDA's clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step ...
HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug Administration, FDA, to initiate a first-in-human Phase ...
FDA’s Rare Disease Innovation Hub Releases Strategic Agenda: Implications for Stakeholders in 2025
In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback